ライフサイエンスコーパス: irritable bowel

1 a significant risk factor for postinfectious irritable bowel and chronic fatigue syndromes.

2 ructive pathologies of the two main forms of irritable bowel disease (IBD), ulcerative colitis (UC),

3 individuals, and those with colon cancer and irritable bowel disease (IBD), we demonstrated that CD4C

4 rylation was observed in colonic mucosa from irritable bowel disease patients.

5 centage of individuals with gastrointestinal/irritable bowel disease.

6 d may offer a therapeutic avenue in treating irritable bowel disease.

7 tive protease pathway in the pathogenesis of irritable bowel disease.

8 n who do not fit a specific disorder such as irritable bowel, functional dyspepsia, or abdominal migr

9 evels of comorbidity included migraine (33), irritable bowel syndrome (17), functional neurological d

10 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

11 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

12 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

13 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

14 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

15 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

16 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

17 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

18 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

19 Irritable bowel syndrome (IBS) affects 7% to 21% of the

20 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

21 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

22 e Rome IV Diagnostic Questionnaire, Rome III irritable bowel syndrome (IBS) and constipation question

23 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

24 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

25 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

26 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

27 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

28 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

29 The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel di

30 Irritable bowel syndrome (IBS) and inflammatory bowel di

31 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

32 Nowadays irritable bowel syndrome (IBS) and lactose intolerance (

33 Irritable bowel syndrome (IBS) and other functional bowe

34 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

35 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

36 Approximately 1 in ten patients with irritable bowel syndrome (IBS) believe their IBS began w

37 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

38 Irritable bowel syndrome (IBS) can be responsible for al

39 Although novel therapies for irritable bowel syndrome (IBS) continue to be developed,

40 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

41 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

42 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

43 Hypnotherapy for irritable bowel syndrome (IBS) has been used primarily i

44 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

45 Patients with irritable bowel syndrome (IBS) have increased postprandi

46 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

47 igenome, and transcriptome in the context of irritable bowel syndrome (IBS) host physiology.

48 and its degree of overlap with dyspepsia and irritable bowel syndrome (IBS) in Nigeria, a typical Afr

49 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

50 Irritable bowel syndrome (IBS) is a chronic functional g

51 Irritable Bowel Syndrome (IBS) is a chronic/common condi

52 Irritable Bowel Syndrome (IBS) is a common condition cha

53 Irritable bowel syndrome (IBS) is a common functional ga

54 Irritable bowel syndrome (IBS) is a common gastrointesti

55 Irritable bowel syndrome (IBS) is a common gastrointesti

56 Irritable bowel syndrome (IBS) is a common, symptom-base

57 Irritable bowel syndrome (IBS) is a functional disorder

58 Irritable bowel syndrome (IBS) is a functional gastroint

59 Irritable Bowel Syndrome (IBS) is a functional somatic s

60 Irritable bowel syndrome (IBS) is a gut-brain disorder i

61 Irritable bowel syndrome (IBS) is a heterogeneous disord

62 Irritable bowel syndrome (IBS) is among the most common

63 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

64 Irritable bowel syndrome (IBS) is characterized by abdom

65 Irritable bowel syndrome (IBS) is characterized by alter

66 Irritable bowel syndrome (IBS) is common but difficult t

67 Irritable bowel syndrome (IBS) is common, affecting 10-2

68 Irritable bowel syndrome (IBS) is more common in patient

69 Irritable bowel syndrome (IBS) is one of the most common

70 Irritable bowel syndrome (IBS) is prevalent in patients

71 Patients with irritable bowel syndrome (IBS) often relate symptoms to

72 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

73 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

74 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

75 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

76 efore aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possib

77 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

78 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

79 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

80 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

81 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

82 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

83 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

84 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

85 ders state that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C)

86 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

87 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

88 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

89 showed the benefit of a 5HT(3) antagonist in irritable bowel syndrome (IBS) with diarrhoea (IBS-D) an

90 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

91 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

92 d neural mechanisms are well-acknowledged in irritable bowel syndrome (IBS), a disorder of brain-gut-

93 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

94 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

95 in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap.

96 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

97 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

98 Certain gut disorders, such as the irritable bowel syndrome (IBS), are associated with elev

99 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

100 bnormal gut-brain interactions are common in irritable bowel syndrome (IBS), but the associations bet

101 Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of eviden

102 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

103 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

104 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

105 on ultimate diagnosis: Crohn's disease (CD), Irritable bowel syndrome (IBS), NSAIDs enteritis (NSAIDs

106 een pathophysiologic factors and symptoms of irritable bowel syndrome (IBS), or whether these factors

107 In patients with irritable bowel syndrome (IBS), pain amplification and h

108 patients with functional dyspepsia (FD) and irritable bowel syndrome (IBS), respectively, as defined

109 Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than

110 In irritable bowel syndrome (IBS), which is the most common

111 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

112 atory bowel diseases (IBD), the reporting of irritable bowel syndrome (IBS)-type symptoms by patients

113 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

114 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

115 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

116 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

117 sing diet in the management of patients with irritable bowel syndrome (IBS).

118 effective in the treatment of patients with irritable bowel syndrome (IBS).

119 agonists might be involved in development of irritable bowel syndrome (IBS).

120 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

121 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

122 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

123 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

124 microbiota might also play a similar role in irritable bowel syndrome (IBS).

125 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

126 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

127 important role in the pathophysiology of the irritable bowel syndrome (IBS).

128 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

129 l nervous system is altered in patients with irritable bowel syndrome (IBS).

130 measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS).

131 he development of drugs for the treatment of irritable bowel syndrome (IBS).

132 ial overgrowth (SIBO) may be associated with irritable bowel syndrome (IBS).

133 risk of gastrointestinal diseases including irritable bowel syndrome (IBS).

134 chologic dysfunction have been implicated in irritable bowel syndrome (IBS).

135 regulated in functional GI disorders such as irritable bowel syndrome (IBS).

136 rrhoea and chronic diarrhoea associated with irritable bowel syndrome (IBS).

137 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

138 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

139 hypersensitivity is common in patients with irritable bowel syndrome (IBS).

140 the progression and evaluate the severity of irritable bowel syndrome (IBS).

141 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

142 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

143 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

144 shown promise in alleviating the symptoms of irritable bowel syndrome (IBS); however, controlled data

145 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

146 red an important pathophysiologic symptom in irritable bowel syndrome (IBS); previous gastrointestina

147 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

148 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

149 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

150 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

151 Management of diarrhoea-predominant irritable bowel syndrome (IBS-D) is generally based on p

152 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

153 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

154 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

155 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

156 The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated

157 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

158 Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel

159 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

160 actor for the development of post-infectious Irritable Bowel Syndrome (PI-IBS).

161 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

162 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

163 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

164 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

165 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

166 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

167 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

168 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

169 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

170 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

171 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

172 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

173 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

174 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

175 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

176 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

177 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

178 Many treatments for irritable bowel syndrome are available to those with the

179 nt evidence to recommend serologic tests for irritable bowel syndrome at this time.

180 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

181 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

182 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

183 ease in IBD risk for persons with a previous irritable bowel syndrome diagnosis.

184 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

185 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

186 Traditionally, irritable bowel syndrome has been considered to be a dis

187 BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to th

188 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

189 microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind,

190 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

191 ased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to

192 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

193 Irritable bowel syndrome is a functional gastrointestina

194 risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people w

195 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

196 Irritable bowel syndrome is characterized by altered sen

197 Irritable bowel syndrome is classified as a functional g

198 toms and the strong overlap between GERD and irritable bowel syndrome is due to the influence of NERD

199 The pathophysiology of irritable bowel syndrome is incompletely understood, but

200 interventions are enjoying a renaissance in irritable bowel syndrome management.

201 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

202 n, Latino individuals, and participants with irritable bowel syndrome or Crohn's disease were more li

203 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

204 Acupuncture for irritable bowel syndrome provided an additional benefit

205 the gut microbiota and the immune system", "irritable bowel syndrome related to gut microbiota", and

206 Irritable bowel syndrome remains an incompletely underst

207 Patients had a greater reduction in irritable bowel syndrome severity scores following the l

208 ficant difference after 4 weeks in change in irritable bowel syndrome severity scores, but significan

209 Identical irritable bowel syndrome symptoms are probably due to di

210 Noninflammatory irritable bowel syndrome was induced by intracolonic ins

211 At 6 months, new diagnoses of irritable bowel syndrome were made in 2 patients (1%) an

212 233 patients with irritable bowel syndrome were randomly allocated to eith

213 n important clinical feature associated with irritable bowel syndrome which in some patients has been

214 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

215 Irritable bowel syndrome with constipation (IBS-C) affec

216 Patients with irritable bowel syndrome with constipation (IBS-C) and p

217 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

218 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

219 ipation, chronic idiopathic constipation, or irritable bowel syndrome with constipation is often made

220 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

221 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

222 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

223 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

224 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

225 a large proportion of people diagnosed with irritable bowel syndrome with diarrhea, a common functio

226 reased loss of bile acids (BAs), overlapping irritable bowel syndrome with diarrhoea (IBS-D).

227 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

228 Irritable bowel syndrome with predominant constipation (

229 The term "irritable bowel syndrome" was used to search Clinical Ev

230 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

231 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

232 titial cystitis/painful bladder syndrome and irritable bowel syndrome) are associated with hyperexcit

233 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

234 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

235 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

236 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

237 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

238 of work on MGBA focused on immunomodulation, irritable bowel syndrome, and neurodevelopmental disorde

239 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

240 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

241 disorders of colonic motor function, such as irritable bowel syndrome, are much more common.

242 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

243 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

244 EC has been implicated in the development of irritable bowel syndrome, but this remains to be confirm

245 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

246 d costs of ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal p

247 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

248 pain - is common in some disorders, such as irritable bowel syndrome, Crohn's disease and pancreatit

249 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

250 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

251 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

252 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

253 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

254 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

255 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

256 disorders of gut-brain interaction, comprise irritable bowel syndrome, functional dyspepsia, abdomina

257 unctional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or funct

258 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

259 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

260 ith active UC, inactive UC, Crohn's disease, irritable bowel syndrome, infectious colitis, and micros

261 various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, an

262 nfection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, po

263 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

264 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

265 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

266 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

267 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

268 Irritable bowel syndrome, which affects 5-10% of the pop

269 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat

270 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

271 sease processes such as neurodegeneration or irritable bowel syndrome.

272 ultimately provide a cure for patients with irritable bowel syndrome.

273 NR1) have been associated with some forms of irritable bowel syndrome.

274 ergrowth participates in the pathogenesis of irritable bowel syndrome.

275 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

276 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

277 findings, are nonspecific, and can simulate irritable bowel syndrome.

278 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

279 cupuncture is a cost-effective treatment for irritable bowel syndrome.

280 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

281 be cost-effective for those with more severe irritable bowel syndrome.

282 other involving children suffering from the irritable bowel syndrome.

283 tion between infection with Blastocystis and irritable bowel syndrome.

284 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

285 e clearly established a genetic component in irritable bowel syndrome.

286 abdominal pain and cramping in patients with irritable bowel syndrome.

287 tem, such as chemotherapy-induced emesis and irritable bowel syndrome.

288 and has been implicated in diseases such as irritable bowel syndrome.

289 oms, such as those regarded as components of irritable bowel syndrome.

290 patients with inflammatory bowel disease and irritable bowel syndrome.

291 n, Crohn's disease, and diarrhea-predominant irritable bowel syndrome.

292 nted Gli binding and showed association with irritable bowel syndrome.

293 functional diarrhea and diarrhea-predominant irritable bowel syndrome.

294 onin antagonists have a therapeutic role for irritable bowel syndrome.

295 ing cancer therapies and in the treatment of irritable bowel syndrome.

296 patients with functional diarrhea, including irritable bowel syndrome.

297 , no tests are available to reliably rule in irritable bowel syndrome.

298 ion (95% CI, 2.3-3.2) visits for symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 mil

299 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

300 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional